Antiviral therapy improves post‐hepatectomy survival in patients with hepatitis B virus‐related hepatocellular carcinoma: a prospective‐retrospective study

Chong, Charing Ching‐Ning; Wong, Grace Lai–Hung; Wong, Vincent Wai‐Sun; Ip, Patrick; Cheung, Yu‐San; Wong, John; Lee, K. F.; Lai, Paul; Chan, Henry Lik‐Yuen

doi:10.1111/apt.13034

Cited by 55 publications

(54 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chong et al treated patients who underwent hepatectomy for HBV-related HCC with oral NAs treatment, including entecavir and lamivudine, and observed that antiviral therapy was associated with better liver function reserve at the time of recurrence. Furthermore, a greater proportion of these patients were able to receive curative treatment for cancer recurrence [29]. This study also suggests that the timing of antiviral therapy (before or after operation) does not make a distinct difference between the hazard ratios.…”

Section: Antiviral Treatment In Hepatectomymentioning

confidence: 64%

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

Section: Antiviral Treatment In Hepatectomymentioning

confidence: 64%

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

“…In patients who have developed HCC, improvements in surgical, locoregional and systemic therapies further contribute to better survival [6]. In addition, antiviral therapy after liver resection may reduce HCC recurrence and mortality [7][8][9].…”

Section: Chronic Hepatitis B Virus (Hbv) Infection Affects Over 350 Mmentioning

confidence: 99%

Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?

Wong

Janssen

2015

Journal of Hepatology

104

111

View full text Add to dashboard Cite

Chronic hepatitis B is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Accurate prediction of HCC risk is important for decisions on antiviral therapy and HCC surveillance. In the last few years, a number of Asian groups have derived and validated several HCC risk scores based on well-known risk factors such as cirrhosis, age, male sex and high viral load. Overall, these scores have high negative predictive values of over 95% in excluding HCC development in 3 to 10 years. The REACH-B score was derived from a community cohort of non-cirrhotic patients and is better applied in the primary care setting. In contrast, the GAG-HCC and CU-HCC scores were derived from hospital cohorts and include cirrhosis as a major integral component. While the latter scores may be more applicable to patients at specialist clinics, the diagnosis of cirrhosis based on routine imaging and clinical parameters can be inaccurate. To this end, recent developments in non-invasive tests of liver fibrosis may further refine the risk prediction. The application of HCC risk scores in patients on antiviral therapy and in other ethnic groups should be evaluated in future studies.

show abstract

“…The etiology of HCC and the severity of cirrhosis are also associated with overall survival in HCC patients [15–17]. The use of postoperative antiviral therapies for viral hepatitis B (HBV)- and hepatitis C (HCV)-related HCC reportedly reduce HCC recurrence and enhance overall survival [18–20]. Different combinations of genes associated with cell proliferation and the tumor microenvironment are also employed as genomic prognostic markers for HCC [21, 22].…”

Section: Introductionmentioning

confidence: 99%

Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection

et al. 2018

View full text Add to dashboard Cite

BackgroundThe predictive factors of overall survival after hepatectomy for HCC remain controversial and need to be investigated.MethodsIn total, 535 consecutive HCC patients undergoing resection were included and their clinicopathological data and overall survival were recorded. Both the tumor and adjacent non-tumor (ANT) tissues were subjected to immunohistochemistry analysis for the expression of autophagy-related markers.ResultsDeath was observed for 219 patients, and the cumulative overall survival rates at 1, 3, 5 and 7 years were 91.0%, 72.3%, 58.8%, and 27.7%, respectively. In the multivariate analysis, mortality was significantly associated with the following: diminished LC3 expression in both the tumor and ANT tissues, in the HCC tissues alone and in the ANT tissues alone (hazard ratio/95% confidence interval: 6.74/2.052–22.19, 6.70/1.321–33.98 and 2.58/1.499–4.915, respectively); recurrent HCC (5.11/3.136–8.342); HBV infection (2.75/1.574–4.784); cirrhosis (1.78/1.059–2.974); and antiviral therapy (0.42/0.250–0.697). The 5-year overall survival rates were 70.2%, 57.3%, 49.6% and 10.7% for patients with positive LC3 expression in both tissue types, in the HCC tissues alone, in the ANT tissues alone, and in neither tissue type, respectively. The 5-year overall survival rates were 56.7%, 47.3%, 51.2% and 38.7% for patients with HBV-related HCC, cirrhosis, no antiviral therapy, and recurrent HCC, respectively, and these rates were significantly lower than those in their counterparts.ConclusionsPatients with recurrent HCC, HBV-related HCC, cirrhosis, and the absence of antiviral therapy showed significantly lower overall survival rates. Furthermore, LC3 expression in both the tumor and liver microenvironments were significantly predictive of overall survival after resection for HCC.

show abstract

Antiviral therapy improves post‐hepatectomy survival in patients with hepatitis B virus‐related hepatocellular carcinoma: a prospective‐retrospective study

Abstract: SUMMARY BackgroundThe effect of antiviral therapy on the post-hepatectomy long-term survival in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remains uncertain.

Cited by 55 publications

References 43 publications

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?

Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection

Contact Info

Product

Resources

About